SEARCH:   Advanced

Blood, 15 November 2008, Vol. 112, No. 10, pp. 3989-3994. Prepublished online as a Blood First Edition Paper on August 29, 2008; DOI 10.1182/blood-2008-06-155820. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2008-06-155820v1 112/10/3989    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kobe, C. Articles by Engert, A. Search for Related Content PubMed PubMed Citation Articles by Kobe, C. Articles by Engert, A. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma Carsten Kobe1, Markus Dietlein1, Jeremy Franklin2, Jana Markova3, Andreas Lohri4, Holger Amthauer5, Susanne Klutmann6, Wolfram H. Knapp7, Josee M. Zijlstra8, Andreas Bockisch9, Matthias Weckesser10, Reinhard Lorenz11, Mathias Schreckenberger12, Roland Bares13, Hans T. Eich14, Rolf-Peter Mueller14, Michael Fuchs2,15, Peter Borchmann2,15, Harald Schicha1, Volker Diehl2, and Andreas Engert2,15 1 Department of Nuclear Medicine, University of Cologne, Cologne, Germany; 2 German Hodgkin Study Group, University of Cologne, Cologne, Germany; 3 Department of Clinical Hematology, Third Faculty of Medicine, Charles University, Prague, Czech Republic; 4 Schweizer Arbeitsgruppe für Klinische Krebsforschung, Bern, Switzerland; 5 Klinik für Strahlenheilkunde, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany; 6 Department of Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 7 Department of Nuclear Medicine, Hanover University Medical School, Hanover, Germany; 8 Department of Hematology, VU University Medical Centre, Amsterdam, The Netherlands; 9 Department of Nuclear Medicine, University of Duisburg-Essen, Essen, Germany; 10 Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany; 11 Department of Nuclear Medicine, University of Wuerzburg, Wuerzburg, Germany; 12 Department of Nuclear Medicine, Gutenberg University Hospital, Mainz, Germany; 13 Department of Nuclear Medicine, University of Tuebingen, Tuebingen, Germany; 14 Department of Radiation Oncology, University of Cologne, Cologne, Germany; and 15 Department I of Internal Medicine, University of Cologne, Cologne, Germany In the HD15 trial of the German Hodgkin Study Group, the negative predictive value (NPV) of positron emission tomography (PET) using [18F]-fluorodeoxyglucose in advanced-stage Hodgkin lymphoma (HL) was evaluated. A total of 817 patients were enrolled and randomly assigned to receive BEACOPP-based chemotherapy. After completion of chemotherapy, residual disease measuring more than or equal to 2.5 cm in diameter was assessed by PET in 311 patients. The NPV of PET was defined as the proportion of PET– patients without progression, relapse, or irradiation within 12 months after PET review panel. The progression-free survival was 96% for PET– patients (95% confidence interval [CI], 94%-99%) and 86% for PET+ patients (95% CI, 78%-95%, P = .011). The NPV for PET in this analysis was 94% (95% CI, 91%-97%). Thus, consolidation radiotherapy can be omitted in PET– patients with residual disease without increasing the risk for progression or early relapse compared with patients in complete remission. The impact of this finding on the overall survival at 5 years must be awaited. Until then, response adapted therapy guided by PET for HL patients seems to be a promising approach that should be further evaluated in clinical trials. This trial is registered at http://isrctn.org study as #ISRCTN32443041 [controlled-trials.com] . CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D.J. Sher, P.M. Mauch, A. Van Den Abbeele, A.S. LaCasce, J. Czerminski, and A.K. Ng Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy Ann. Onc., June 18, 2009; (2009) mdp071v1. [Abstract] [Full Text] [PDF] W. A. Weber Assessing Tumor Response to Therapy J. Nucl. Med., May 1, 2009; 50(Suppl_1): 1S - 10S. [Abstract] [Full Text] [PDF] M. Hutchings and S. F. Barrington PET/CT for Therapy Response Assessment in Lymphoma J. Nucl. Med., May 1, 2009; 50(Suppl_1): 21S - 30S. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020